Karen T. Tashima - Concepedia

Author

Karen T. Tashima

Also Known As

Andrade, Adriana, Breno Santos, Denis Tarakjian, Greenblatt, David J., Herbert Davis, Hodder, Sally, Judith S Currier, K T Tashima, K T. Tashima, K Tashima

163

Publications

9.3K

Citations

H-Index

156

Concepts

All Affiliations

Brown University Miriam Hospital Harvard University Providence College Brigham and Women's Hospital

About

Karen T. Tashima is an author at Brown University specializing in medicine, hiv, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	32	2.6K
2	Public Health	8	8	1.2K
3	Health Sciences	3	3	236
4	Arts	1	1	54
5	Nursing	1	1	36

Karen T. Tashima

Publications

7.8K

Citations

H-Index

Page 1

	Year	Citations
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Jason D. Goldman, David Chien Lye, David S.C. Hui, New England Journal of Medicine	2020	1.4K
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults Schlomo Staszewski, Javier O Morales-Ramirez, Karen T. Tashima, New England Journal of Medicine	1999	1K
Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America Samir K. Gupta, Joseph A. Eustace, Jonathan Winston, Clinical Infectious Diseases HypertensionImmunodeficienciesRenal PathologyImmunologyRenal Inflammation	2005	583
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, The Lancet Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials	2018	371
Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals David B. Clifford, Scott Evans, Yijun Yang, Annals of Internal Medicine	2005	270
Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study Heather J. Ribaudo, David W. Haas, C. Tierney, Clinical Infectious Diseases	2006	220
Brief Report David A. Wohl, Shinichi Oka, Nathan Clumeck, JAIDS Journal of Acquired Immune Deficiency Syndromes Double-blinded Phase 3Initial Hiv-1 TreatmentTaf ArmTreatment And PreventionMedicine	2016	178
Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results Paul E. Sax, Camlin Tierney, Ann C. Collier, The Journal of Infectious Diseases	2011	176
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial Jean‐Michel Molina, Kathleen Squires, Paul E. Sax, The Lancet HIV Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyNon-inferiority Trial	2018	140
Phase variation in <i>tcpH</i> modulates expression of the ToxR regulon in <i>Vibrio cholerae</i> P. Carroll, Karen T. Tashima, Marc B. Rogers, Molecular Microbiology	1997	136

Page 1